HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Conditions
- Interventions
- Registration Number
- NCT06744556
- Brief Summary
Acute myeloid leukemia (AML) represents the most prevalent leukemia type in China. Elderly patients (≥60 years old) have a high incidence rate, accounting for over half of all AML patients, with a median age of onset approximately 68 years. Elderly AML patients have a poor prognosis and are often accompanied with multiple high-risk factors.The 5-year overall...
- Detailed Description
This study is a multicenter, prospective, randomized, and controlled clinical trial, which intends to enroll elderly patients diagnosed with AML in accordance with the WHO (2022) or ICC standards and are suitable for intensive chemotherapy. For patients meeting the inclusion and not meeting the exclusion criteria, they will be randomly grouped and respective...
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Conforming to the diagnostic criteria of AML or MDS/AML by WHO (2022) or ICC.
- Age ≥ 60 years and ≤ 75 years, regardless of gender.
- The performance status assessment of the Eastern Cooperative Oncology Group (ECOG-PS) is 0 - 2.
- Meeting the requirements of the following laboratory examination indicators (performed within 7 days before treatment):
- Total bilirubin ≤ 1.5 times the upper limit of normal for the same age group; 2) AST and ALT ≤ 2.5 times the upper limit of normal for the same age group; 3) Serum creatinine < 2 times the upper limit of normal for the same age group; 4) Cardiac enzymes < 2 times the upper limit of normal for the same age group; 5) The cardiac ejection fraction determined by echocardiography (ECHO) > 50%. The informed consent form must be signed before the initiation of all specific research procedures. It should be signed by the patient himself/herself or an immediate family member. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the disease, the informed consent form should be signed by the legal guardian or an immediate family member of the patient.
- Acute promyelocytic leukemia accompanied by the PML-RARA fusion gene
- Acute myeloid leukemia accompanied by the RUNX1-RUNX1T1 or CBFB-MYH11 fusion gene
- Acute myeloid leukemia accompanied by the BCR-ABL fusion gene
- Retreated patients (referring to those who have previously undergone induction chemotherapy but can receive hydroxyurea for cytoreduction).
- Patients concurrently suffering from malignant tumors in other organs (requiring treatment).
- Active cardiac diseases, defined as one or more of the following:
- Uncontrolled or symptomatic angina pectoris history; 2) Myocardial infarction less than 6 months from the time of enrollment in the study; 3) History of arrhythmias requiring drug treatment or with severe clinical symptoms; 4) Uncontrolled or symptomatic congestive heart failure (> NYHA Grade 2);
-
Severe infectious diseases (untreated tuberculosis, pulmonary aspergillosis).
-
Those considered ineligible for enrollment by the researcher.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description DAV/IAV daunorubicin Induction therapy: Ara-C 100mg/m2/d, d1-5 Daunorubicin 60mg/m2/d, d1-2 or Idarubicin 10mg/m2/d, d1-2 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If the treatment achieves CR/CRi/CRh, proceed directly to consolidation therapy. If the treatment does not achieve CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second Induction Phase: For patients with FLT3 or IDH1 mutations, targeted therapy can be chosen. If there is no FLT3 or IDH1 mutation or the patient is unwilling to use FLT3 or IDH1 inhibitors, switch to the HAV induction regimen. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA regimen: 6 courses Azacitidine 75 mg/m2/d on days 1-5, Venetoclax 400 mg on days 1-7. DAV/IAV Venetoclax Induction therapy: Ara-C 100mg/m2/d, d1-5 Daunorubicin 60mg/m2/d, d1-2 or Idarubicin 10mg/m2/d, d1-2 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If the treatment achieves CR/CRi/CRh, proceed directly to consolidation therapy. If the treatment does not achieve CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second Induction Phase: For patients with FLT3 or IDH1 mutations, targeted therapy can be chosen. If there is no FLT3 or IDH1 mutation or the patient is unwilling to use FLT3 or IDH1 inhibitors, switch to the HAV induction regimen. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA regimen: 6 courses Azacitidine 75 mg/m2/d on days 1-5, Venetoclax 400 mg on days 1-7. DAV/IAV cytarabine Induction therapy: Ara-C 100mg/m2/d, d1-5 Daunorubicin 60mg/m2/d, d1-2 or Idarubicin 10mg/m2/d, d1-2 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If the treatment achieves CR/CRi/CRh, proceed directly to consolidation therapy. If the treatment does not achieve CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second Induction Phase: For patients with FLT3 or IDH1 mutations, targeted therapy can be chosen. If there is no FLT3 or IDH1 mutation or the patient is unwilling to use FLT3 or IDH1 inhibitors, switch to the HAV induction regimen. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA regimen: 6 courses Azacitidine 75 mg/m2/d on days 1-5, Venetoclax 400 mg on days 1-7. DAV/IAV azacitidine Induction therapy: Ara-C 100mg/m2/d, d1-5 Daunorubicin 60mg/m2/d, d1-2 or Idarubicin 10mg/m2/d, d1-2 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If the treatment achieves CR/CRi/CRh, proceed directly to consolidation therapy. If the treatment does not achieve CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second Induction Phase: For patients with FLT3 or IDH1 mutations, targeted therapy can be chosen. If there is no FLT3 or IDH1 mutation or the patient is unwilling to use FLT3 or IDH1 inhibitors, switch to the HAV induction regimen. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA regimen: 6 courses Azacitidine 75 mg/m2/d on days 1-5, Venetoclax 400 mg on days 1-7. DAV/IAV Idarubicin Induction therapy: Ara-C 100mg/m2/d, d1-5 Daunorubicin 60mg/m2/d, d1-2 or Idarubicin 10mg/m2/d, d1-2 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If the treatment achieves CR/CRi/CRh, proceed directly to consolidation therapy. If the treatment does not achieve CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second Induction Phase: For patients with FLT3 or IDH1 mutations, targeted therapy can be chosen. If there is no FLT3 or IDH1 mutation or the patient is unwilling to use FLT3 or IDH1 inhibitors, switch to the HAV induction regimen. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA regimen: 6 courses Azacitidine 75 mg/m2/d on days 1-5, Venetoclax 400 mg on days 1-7. HAV Venetoclax Induction Therapy: Ara-C 100mg/m2/d, d1-5 HHT 2mg/m2/d, d1-5 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If CR/CRi/CRh is achieved, proceed directly to consolidation therapy. If the treatment does not reach CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second course: For patients with FLT3 or IDH1 mutations, the corresponding targeted therapy can be selected, as before. For patients without FLT3 or IDH1 mutations or those who do not want to use FLT3 or IDH1 inhibitors, the DAV/IAV induction regimen is changed. If the treatment does not reach CR/CRi/CRh after two courses, the patient is discharged. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA : 6 courses HAV cytarabine Induction Therapy: Ara-C 100mg/m2/d, d1-5 HHT 2mg/m2/d, d1-5 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If CR/CRi/CRh is achieved, proceed directly to consolidation therapy. If the treatment does not reach CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second course: For patients with FLT3 or IDH1 mutations, the corresponding targeted therapy can be selected, as before. For patients without FLT3 or IDH1 mutations or those who do not want to use FLT3 or IDH1 inhibitors, the DAV/IAV induction regimen is changed. If the treatment does not reach CR/CRi/CRh after two courses, the patient is discharged. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA : 6 courses HAV azacitidine Induction Therapy: Ara-C 100mg/m2/d, d1-5 HHT 2mg/m2/d, d1-5 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If CR/CRi/CRh is achieved, proceed directly to consolidation therapy. If the treatment does not reach CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second course: For patients with FLT3 or IDH1 mutations, the corresponding targeted therapy can be selected, as before. For patients without FLT3 or IDH1 mutations or those who do not want to use FLT3 or IDH1 inhibitors, the DAV/IAV induction regimen is changed. If the treatment does not reach CR/CRi/CRh after two courses, the patient is discharged. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA : 6 courses HAV Homoharringtonine Induction Therapy: Ara-C 100mg/m2/d, d1-5 HHT 2mg/m2/d, d1-5 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If CR/CRi/CRh is achieved, proceed directly to consolidation therapy. If the treatment does not reach CR/CRi/CRh, enter the second induction phase with a different treatment regimen. Second course: For patients with FLT3 or IDH1 mutations, the corresponding targeted therapy can be selected, as before. For patients without FLT3 or IDH1 mutations or those who do not want to use FLT3 or IDH1 inhibitors, the DAV/IAV induction regimen is changed. If the treatment does not reach CR/CRi/CRh after two courses, the patient is discharged. Consolidation therapy: 1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older) Maintenance therapy: VA : 6 courses
- Primary Outcome Measures
Name Time Method Event-free survival (EFS) Up to approximately 1 years after the date of the last enrolled participants It is defined as the time from the start of randomization to the occurrence of induction failure or disease progression or death from any cause (whichever occurs first)
- Secondary Outcome Measures
Name Time Method Complete remission (CR) rate or complete remission with partial hematologic recovery (CRh) rate or complete remission with incomplete hematologic recovery (CRi) rate Up to approximately eight weeks afer induction therapy Proportion of patients with CR, CRh or CRi
Undectable Minimal residual disease (MRD) by flow cytometry compelete remission rates after induction Up to approximately eight weeks afer induction therapy Among those who have achieved CR/CRh/CRi after induction, proportion of patients who is undectable MRD by flow cytometry
Undectable Minimal residual disease (MRD) by flow cytometry complete remission rates in the whole treatment up to 1 years after the date of the last enrolled participants Among those who have achieved CR/CRh/CRi in the whole treatment, proportion of patients who is undectable MRD by flow cytometry
Relapse-free Survival (RFS) Up to approximately 1 years after the date of the last enrolled participants It is defined as the time from the start of achieving remission to disease progression, death from any cause or the last follow-up.
30-day postinduction mortality Up to approximately 30 days It is defined as death from any cause within 30 days after the start of induction.
60-day postinduction mortality Up to approximately 60 days It is defined as death from any cause within 60 days after the start of induction.
overall survival up to 1 years after the date of the last enrolled participants The interval from the date of enrollment to the date of death or the date of last follow-up, whichever occurred first.